Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Btk inhibitors

a pyridine ring and inhibitor technology, applied in the field of 65 membered fused pyridine ring compounds, can solve the problems of serious adverse effects, prohibitive development of btk inhibitors, and fyn-deficient mice also show pronounced neurological defects,

Inactive Publication Date: 2014-08-07
MERCK SHARP & DOHME CORP +1
View PDF0 Cites 46 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about compounds that can stop Btk from working, and how they can be used to treat diseases caused by Btk activity, like autoimmune diseases and inflammatory diseases. The text also describes pharmaceutical compositions that can contain these compounds and some other substances.

Problems solved by technology

With dramatic adverse effects reported for knockouts of Src-family kinases, especially for double and triple knockouts, this is seen as prohibitive for the development of Btk inhibitors that are not selective over the Src-family kinases.
In addition, Fyn-deficient mice also show pronounced neurological defects.
Hence, an inhibitor that inhibits multiple or all kinases of the Src-family kinases simultaneously may cause serious adverse effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Btk inhibitors
  • Btk inhibitors
  • Btk inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

[1266]

4-(8-amino-3-((trans)-4-hydroxycyclohexyl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide

[1267](trans)-4-(8-Amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)cyclohexyl acetate (0.129 mmol, 40 mg) and 4-(pyridin-2-yl-aminocarbonyl)benzeneboronic acid (0.14 mmol, 45.8 mg) were suspended in a mixture of 2N aqueous potassium carbonate solution (0.386 mmol, 193 μL) dioxane (6 mL) and water (3 mL). Nitrogen was bubbled through the mixture, followed by the addition of 1,1′-bis(diphenylphosphino)-ferrocene palladium (II) chloride (0.013 mmol, 10.39 mg). The reaction mixture was stirred at 100° C. overnight. Water was added to the reaction mixture, followed by an extraction with ethyl acetate (2×). The combined organic layer was washed with brine, dried over magnesium sulfate and evaporated. After evaporation, the residue was purified by preparative HPLC. Fractions containing product were collected and lyophilized to afford 27 mg of 4-(8-amino-3-((trans)-4-hydroxycyclohexyl)-imidazo[1,5-a...

example 2

[1268]

4-(8-amino-3-((trans)-4-hydroxycyclohexyl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide

[1269]This compound was prepared in an analogous manner as described in Example 1, from Intermediate 1 and Intermediate D, to afford the title compound (4.2 mg, 6.6%). Data: UPLC(C) Rt: 2.05 min; m / z 497.2 (M+H)+.

example 3

[1270]

4-(8-amino-3-((trans)-4-hydroxycyclohexyl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-propylpyridin-2-yl)benzamide

[1271]This compound was prepared, in an analogous manner as described in Example 1, from Intermediate 1 and Intermediate C, to afford the title compound (10.6 mg, 17.5%). Data: UPLC(C) Rt: 1.44 min; m / z 471.3 (M+H)+.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Electric chargeaaaaaaaaaa
Electric chargeaaaaaaaaaa
Electric chargeaaaaaaaaaa
Login to View More

Abstract

Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Description

FIELD OF THE INVENTION[0001]The present invention relates to 6-5 membered fused pyridine ring compounds, to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.BACKGROUND OF THE INVENTION[0002]B lymphocyte activation is key in the generation of adaptive immune responses. Derailed B lymphocyte activation is a hallmark of many autoimmune diseases and modulation of this immune response is therefore of therapeutic interest. Recently the success of B cell therapies in autoimmune diseases has been established. Treatment of rheumatoid arthritis (RA) patients with Rituximab (anti-CD20 therapy) is an accepted clinical therapy by now. More recent clinical trial studies show that treatment with Rituximab also ameliorates disease symptoms in relapsing remitting multiple sclerosis (RRMS) and sys...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D487/04C07D513/04A61K31/55A61K31/5377A61K31/53A61K31/4985A61K31/541
CPCC07D487/04A61K31/4985C07D513/04A61K31/541A61K31/5377A61K31/53A61K31/55A61K45/06C07D519/00A61P1/04A61P1/18A61P3/10A61P7/00A61P7/02A61P7/04A61P7/06A61P9/00A61P11/00A61P11/02A61P11/08A61P13/12A61P17/00A61P17/04A61P17/06A61P17/16A61P19/02A61P19/06A61P19/08A61P21/04A61P25/00A61P25/28A61P27/02A61P27/16A61P29/00A61P31/00A61P35/00A61P37/00A61P37/08A61P43/00C07D471/04
Inventor DE MAN, ADRIANUS PETRUS ANTONIUSSTERRENBURG, JAN-GERARDRAAIJMAKERS, HAN C.A.KAPTEIN, ALLARDOUBRIE, ARTHURA A.REWINKEL, JOHANNES BERNARDUS MARIAJANS, CHRISTIAAN GERARDUS JOHANNES MARIAWIJKAMANS, JACOBUS C.H.M.BARF, TJEERD A.COOPER, ALAN B.KIM, RONALD M.BOGA, SOBHANA BABUZHU, HUGH Y.GAO, XIAOLEIYAO, XINANAND, RAJANWULIU, SHILANYANG, CHUNDAOALHASSAN, ABDUL-BASITWANG, JAMESYU, YOUNONGLIU, JIANVACCARO, HENRY M.
Owner MERCK SHARP & DOHME CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com